Metropolis Healthcare Limited METROPOLIS NSEPHARMA

Healthcare · Diagnostics & Research · India

https://www.metropolisindia.com

Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India, Africa, South Asia, the Middle East, and internationally. The company offers routine and semi-specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; and clinical trial research, hospital lab management, and home collection services, as well as profiles, blood tests, and soft radiology services. It also provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, youth, and corporates. In addition, the company develops and deals in technology driven products and services. The company serves a range of customers, including direct-to-consumer diagnostics through patient service centers, a mobile app, a website, and home collection; partnerships with standalone labs, hospital chains, and diagnostic networks; and institutional clients, such as corporates, government bodies, and hospital lab management services. Metropolis Healthcare Limited was founded in 1980 and is headquartered in Mumbai, India.

Market & Price

Market Cap

₹11,514.18 Cr

Current Price

₹555.35

High / Low (52W)

₹558.80 / ₹411.38

Beta

0.14

Valuation

Stock P/E

60.63

Industry PE

37.60

Forward P/E

36.64

PEG Ratio

Book Value

₹73.13

Price to Book

7.59

P/S

7.00

EV/EBITDA

28.77

Dividend Yield

0.36%

Profitability & Returns

ROCE

15.73%

ROE

13.37%

ROA

8.34%

Profit Margin

11.54%

Op Margin

16.35%

EPS (Latest Qtr)

₹2.46

EPS (TTM)

₹9.16

Balance Sheet & Liquidity

Debt/Equity

0.15

Quick Ratio

1.12

Current Ratio

1.40

Debt

₹231.91 Cr

Total Assets

₹2,138.05 Cr

Current Assets

₹468.61 Cr

Working Capital

₹134.59 Cr

Ownership

Promoter Holding

48.87%

Chg in Prom Hold

FII / Inst Holding

44.53%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹11,531.80 Cr

Total Revenue (TTM)

₹1,645.85 Cr

EBITDA

₹400.85 Cr

Free Cash Flow

₹242.37 Cr

Operating Cash Flow

₹350.70 Cr

Shares Outstanding

₹20.73 Cr

Gross Margin

80.28%

Payout Ratio

10.88%

Growth (CAGR)

Revenue 5Y

12.75%

Profit 5Y

9.97%

Revenue (YoY)

23.00%

Earnings (YoY)

73.00%

PROS

Compounding revenue at 12.8% over 5 years.
Generates positive free cash flow.

CONS

Trading at a high P/E of 60.6.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	METROPOLIS Metropolis Healthcare Limited NSEPHARMA	555.35	60.63	₹11,514.18 Cr	0.36%	15.73%	13.37%	12.75%	9.97%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	322.77 Cr	345.29 Cr	386.06 Cr	-	405.91 Cr	424.68 Cr
Cost of Revenue	66.94 Cr	73.59 Cr	84.72 Cr	-	87.29 Cr	82.79 Cr
Gross Profit	255.82 Cr	271.70 Cr	301.34 Cr	-	318.62 Cr	341.89 Cr
Operating Expenses	211.51 Cr	238.03 Cr	242.43 Cr	-	255.65 Cr	272.47 Cr
Operating Income	44.31 Cr	33.67 Cr	58.91 Cr	-	62.97 Cr	69.43 Cr
EBITDA	74.56 Cr	69.27 Cr	97.27 Cr	-	94.77 Cr	116.29 Cr
Interest Expense	4.53 Cr	4.60 Cr	5.20 Cr	-	5.73 Cr	7.93 Cr
Pretax Income	42.34 Cr	36.04 Cr	61.23 Cr	-	57.16 Cr	69.76 Cr
Tax Provision	10.86 Cr	6.81 Cr	15.99 Cr	-	15.07 Cr	18.80 Cr
Net Income	31.36 Cr	29.14 Cr	45.06 Cr	-	41.39 Cr	50.90 Cr
Diluted EPS	-	1.42	2.17	2.53	1.99	2.46

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	1,148.21 Cr	1,207.71 Cr	1,331.20 Cr	1,645.85 Cr
Cost of Revenue	-	263.69 Cr	260.72 Cr	278.88 Cr	347.52 Cr
Gross Profit	-	884.52 Cr	946.99 Cr	1,052.32 Cr	1,298.32 Cr
Operating Expenses	-	675.70 Cr	743.59 Cr	858.00 Cr	1,031.20 Cr
Operating Income	-	208.82 Cr	203.40 Cr	194.31 Cr	267.12 Cr
EBITDA	-	303.52 Cr	291.69 Cr	318.11 Cr	417.44 Cr
Interest Expense	-	26.80 Cr	22.54 Cr	18.57 Cr	24.54 Cr
Pretax Income	-	187.50 Cr	174.69 Cr	190.85 Cr	259.18 Cr
Tax Provision	-	44.11 Cr	46.23 Cr	45.34 Cr	67.99 Cr
Net Income	-	142.88 Cr	127.82 Cr	144.97 Cr	190.02 Cr
Diluted EPS	-	6.95	6.22	7.04	9.19

Compounded Sales Growth

5 Years:	12.75%
1 Year:	23.00%

Compounded Profit Growth

5 Years:	9.97%
1 Year:	73.00%

Stock Price Performance

1 Year:	+33.02%
6 Months:	+14.02%
3 Months:	+17.48%
1 Month:	+16.78%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	1,501.61 Cr	1,555.06 Cr	1,867.34 Cr	2,138.05 Cr
Current Assets	-	302.73 Cr	315.83 Cr	345.94 Cr	468.61 Cr
Cash & Equivalents	-	68.83 Cr	62.62 Cr	39.48 Cr	54.78 Cr
Inventory	-	44.59 Cr	38.69 Cr	47.84 Cr	45.49 Cr
Receivables	-	121.89 Cr	126.28 Cr	147.95 Cr	170.29 Cr
Total Liabilities	-	510.90 Cr	455.79 Cr	532.70 Cr	613.50 Cr
Current Liabilities	-	264.97 Cr	245.87 Cr	294.33 Cr	334.02 Cr
Long Term Debt	-	28.61 Cr	0	5.27 Cr	0
Total Debt	-	266.38 Cr	197.06 Cr	204.13 Cr	231.91 Cr
Total Equity	-	988.23 Cr	1,096.16 Cr	1,330.97 Cr	1,513.16 Cr
Shares Outstanding	-	20.48 Cr	20.49 Cr	20.72 Cr	20.73 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	247.09 Cr	264.07 Cr	262.75 Cr	350.70 Cr
Investing Cash Flow	-	46.79 Cr	-89.41 Cr	-201.06 Cr	-223.13 Cr
Financing Cash Flow	-	-292.33 Cr	-181.20 Cr	-86.63 Cr	-115.29 Cr
Capital Expenditure	-	-52.63 Cr	-63.76 Cr	-68.61 Cr	-51.18 Cr
Free Cash Flow	-	194.46 Cr	200.31 Cr	194.13 Cr	299.51 Cr
Net Change in Cash	-	1.56 Cr	-6.54 Cr	-24.94 Cr	12.28 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	77.0%	78.4%	79.1%	78.9%
Operating Margin %	-	18.2%	16.8%	14.6%	16.2%
Net Margin %	-	12.4%	10.6%	10.9%	11.5%
ROE %	-	14.5%	11.7%	10.9%	12.6%
ROCE %	-	16.9%	15.5%	12.4%	14.8%

Shareholding Pattern

Insiders

48.87%

Institutions

44.53%

Public Float

87.08%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for METROPOLIS

No recent headlines available.

METROPOLIS · Healthcare